Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

200.40GBp
15 Oct 2018
Change (% chg)

0.80 (+0.40%)
Prev Close
199.60
Open
196.65
Day's High
202.30
Day's Low
193.55
Volume
2,012,700
Avg. Vol
3,646,192
52-wk High
504.60
52-wk Low
169.30

Select another date:

Thu, Sep 27 2018

BUZZ-HSBC hikes PT for India's Dr.Reddy's, says optimism continues on critical ANDAs

** HSBC raises target price for Dr.Reddy's Laboratories Ltd to 2,315 rupees from 2,165 rupees, maintains rating at "hold"

Indivior sharply lowers revenue outlook for opioid addiction drug Sublocade

Sept 26 Indivior Plc revised its full-year earnings guidance as it sharply lowered its revenue expectation for opioid addiction drug Sublocade on Wednesday.

Teva to hold Indivior generic drug launch pending U.S. ruling

Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Teva to hold Indivior generic drug launch pending U.S. ruling

Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

UPDATE 1-Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

Aug 8 The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Indivior: U.S. court rules against generic rival's appeal

Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

Indivior: U.S. court rules against generic rival's appeal

Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

Select another date: